安宫牛黄丸干预新型冠状病毒感染的回顾性临床研究  

Retrospective Clinical Study on the Intervention of Angong Niuhuang Pills in Patients Infected with COVID-19

作　　者：张静[1] 刘云涛 水敬伟 郑丹文 叶钢福 陈秋旻 李鹏飞 黄建山 王敏[2] 王佳梅 马增明 郑贺阳 范刚 颜智力 林宝华[4] 黄和贤[11] 高全达 李尝赐 王斌 符茂东 洪江从 蔡扬帆 张旺生[17] 吴仕明 张忠德 Zhang Jing;Liu Yuntao;Shui Jingwei;Zheng Danwen;Ye Gangfu;Chen Qiumin;Li Pengfei;Huang Jianshan;Wang Min;Wang Jiamei;Ma Zengming;Zheng Heyang;Fan Gang;Yan Zhili;Lin Baohua;Huang Hexian;Gao Quanda;Li Changci;Wang Bin;Fu Maodong;Hong Jiangcong;Cai Yangfan;Zhang Wangsheng;Wu Shiming;Zhang Zhongde(Xiamen Traditional Chinese Medicine Hospital,Fujian,Xiamen 361000,China)

机构地区：[1]福建省厦门市中医院,福建厦门361000 [2]广州中医药大学,广东广州510006 [3]广州中医药大学第二附属医院,广东广州510120 [4]厦门大学附属第一医院杏林分院,福建厦门361000 [5]厦门大学附属翔安医院,福建厦门361000 [6]福建省厦门市第五医院,福建厦门361000 [7]福建省厦门市仙岳医院,福建厦门361000 [8]福建省厦门莲花医院,福建厦门361000 [9]福建省厦门锦园中医院,福建厦门361000 [10]福建省厦门思明南普陀中医院,福建厦门361000 [11]厦门大学附属中山医院,福建厦门361000 [12]厦门医学院附属第二医院,福建厦门361000 [13]福建省厦门市海沧医院,福建厦门361000 [14]福建省厦门长庚医院,福建厦门361000 [15]复旦大学附属中山医院厦门医院,福建厦门361000 [16]福建中医药大学附属康复医院,福建福州350003 [17]福建中医药大学附属第二人民医院,福建福州350003 [18]福建医科大学孟超肝胆医院,福建福州350003

出　　处：《中国中医急症》2024年第7期1129-1133,1155,共6页Journal of Emergency in Traditional Chinese Medicine

基　　金：国家中医药管理局“新型冠状病毒感染肺炎中医药应急专项”课题(2021ZYLCYJ04-1);2022厦门市医疗卫生指导性项目(3502Z20224ZD1165);厦门市第六批中医后备人才项目(厦卫中医[2022]136号);2023厦门市扶持中医药发展专项(XWZY-2023-0612)。

摘　　要：目的分析安宫牛黄丸的使用与新型冠状病毒感染重症结局的相关性。方法采用病例对照试验设计,收集新型冠状病毒感染患者基本信息、中医辨证信息、安宫牛黄丸的治疗信息、疾病进展信息等。以是否转重症为结局变量,采用二元非条件逐步Logistic回归方法进行安宫牛黄丸是否用药以及安宫牛黄丸不同用药时机的相关性分析。结果纳入最终诊断为营血分证并具有发热症状者156例,倾向性评分匹配,安宫牛黄丸用药组35例,未用药组35例;Logistic分析结果未发现服用安宫牛黄丸与重症结局有相关性(P=0.330);进一步对安宫牛黄丸不同用药时间与重症结局的相关性进行分析,用药时间对重症结局可能存在影响(P=0.002),营血分证后用药组发生重症的风险是营血分证前用药组的9.308倍。结论安宫牛黄丸早期干预新型冠状病毒感染可能降低疾病转重症的风险。Objective:To analyze the correlation between the use of Angong Niuhuang Pills(ANP)and severe outcomes in patients infected with COVID-19.Methods:A case-control study design was employed,and data such as patients'basic information,traditional Chinese medicine(TCM)syndrome differentiation,treatment details involving ANP,and disease progression were collected.The outcome variable was defined as whether or not the pa-tient developed severe llness.Binary unconditional stepwise logistic regression was used to analyze the correlation between ANP administration,timing of ANP use,and severe disease outcomes.Results:A total of 156 cases were included,all diagnosed with Yingfen and Xuefen syndromes presenting with fever symptoms.After propensity score matching,35 cases were in the ANP treatment group and 35 in the non-treatment group.Logistic analysis did not reveal a significant correlation between ANP usage and severe outcomes(P=0.330).However,further anal-ysis of the association between different timings of ANP administration and severe outcomes suggested a potential impact of timing(P=0.002),with patients who received ANP after the onset of Yingfen and Xuefen syndromes hav-ing a 9.308 times higher risk of developing severe illness compared to those treated before the onset.Conclusion:Early intervention with ANP in COVID-19 infection may reduce the risk of disease progression to severe stages.

关 键 词：新型冠状病毒感染 早期干预 安宫牛黄丸 

分 类 号：R511[医药卫生—内科学]